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ABSTRACT
Objective: Human cytomegalovirus (CMV) is the most common cause of viral intrauterine infec-
tions in the world. Herpes simplex virus type 2 (HSV-2) and human papillomavirus (HPV) are 
the main agents of viral sexually transmitted diseases, which cause genital ulcers and genital warts, 
respectively. HPV infection has been linked to the majority of the anogenital malignancies. The aim 
of this study was to detect the existence of CMV, HSV-2 and HPV type 16-18 in Turkish pregnants 
by using sensitive molecular assays. Methods: One hundred thirty-four women (18-41 years old; 
mean age ± SD: 27 ± 8) applied to outpatient clinic of Obstetrics and Gynecology, in between 18th 
- 22nd weeks of their pregnancy and a control group of 99 healthy women (15-39 years old; mean 
age ± SD: 24 ± 8) were included in the study. Cervical smear samples were used for DNA extrac-
tion. CMV, HSV-2 and HPV 16-18 detections were carried out by real time PCR and in house PCR 
method, respectively. Results: Three patients (3/134; 2.2%) were found to be positive for each HPV 
and HSV-2. Dual infection with HPV and HSV was found in just one patient. HPV 18 was detected 
in all positive samples. CMV was found to be positive in two patients (2/134; 1.4 %). Conclusion: 
HPV, HSV and CMV must be screened due to high prevalence of these viruses in pregnants by using 
sensitive molecular methods. 
Keywords: pregnancy; infection; polymerase chain reaction.
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INTRODUCTION
Cytomegalovirus (CMV) is the most common 
cause of congenital infections affecting 0.5% to 
2% of all live births in the developed world.1 
Intrauterine infection occurs in up to 50% of 
pregnancies following primary maternal infec-
tion, and 10% of the infected infants are symp-
tomatic at birth.2,3 However nearly 10%-15% 
of the asymptomatic newborns develop late se-
quelae, particularly sensorineural hearing loss 
and neurodevelopmental disorders.4 
Genital herpes continues to be a public 
health problem in both developed and devel-
oping countries. Prevalence of HSV-2 in dif-
ferent populations has shown various results 
from less than 10% to more than 40%.5 Labo-
ratory confi rmation for clinical diagnosis of 
HSV-2 is important, particularly as there are 
other conditions which present similarly to 
genital herpes, while atypical presentations 
of genital herpes also occur.6 
Uterine cervix carcinoma is the second 
most common type of female cancers and 
also the second highest mortality cause for 
women. Human papillomavirus (HPV) be-
ing detected in close to 99.7% of cervical 
squamous cell carcinomas is imputed to be 
a necessary factor that causes cervix carcino-
ma. Hormones and their metabolism altera-
tion have also been implicated as cofactors 
in HPV proliferation and the cervical cancer 
pathogenesis. It is well known that high risk 
HPV infections are more frequent in preg-
nant women.7-9 The polymerase chain reac-
tion (PCR) technology for CMV, HSV, HPV 
detection is now highly sensitive and can de-
tect viral DNA in exfoliated cells irrespective 
of the sampling method used.10 
The aim of this study was to detect CMV, 
HSV-2, and HPV type 16-18 from cervical 
smear samples of pregnant women by PCR 
based methods and to improve an algorithm 
for follow-up of positive patients.
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MATERIAL AND METHODS
Study group 
This study was performed at the Gynecology and Obstet-
rics Outpatient Clinic at Gazi University Hospital, An-
kara, Turkey. One hundred thirty-four women (18-41 
years old; mean age ± SD: 27 ± 8) applied to outpatient 
clinic, in between 18th - 22nd weeks of their pregnan-
cy and a control group of 99 healthy women (15-39 years 
old; mean age ± SD: 24 ± 8) followed for routine pre-
natal visit, were included in the study. Cervical smear 
samples were used to detect CMV, HSV-2 and HPV. 
All the patients and the control group answered a ques-
tionnaire including age of first sexual intercourse, number 
of sexual partners and condom use.
Specimen sampling and preservation
Cervical smear samples collected by sterile swabs were sent 
to the laboratory in phosphate buffered saline (PBS) (pH 
8.6). The samples in PBS were vortexed and stored in -86°C 
until they were tested. And 10 mL of blood was taken 
from each patient for serological examination of HSV-2.
DNA extraction method for HPV, HSV and CMV
Following the centrifugation at 13,000 rpm for 3 min, the 
samples in PBS were treated with lysis solution contain-
ing 20 mg/mL proteinase K [20 mM (NH4)2SO4, 75 
mM Tris HCl (pH 8.8) 0,1% Tween 20]. After discarding 
the supernatant, precipitate was extracted by phenol-
chloroform isoamyl alcohol method.11 Precipitation of 
DNA was succeeded by using absolute ethanol including 
3M sodium acetate at -20°C overnight. On the following 
day, samples were mixed with 70% alcohol and dried. 
After drying, they were incubated on dry block at 55°C 
for 10 min and then 50 µL sterile deionised water was 
added. 
Amplification of HPV DNA
The primers used in this study were the consensus primers 
for all HPV genotypes and were chosen from L1 location 
of HPV genome which is associated with major viral cap-
sid protein metabolism. MY09/MY11 primers were used 
for amplifi cation of HPV.12 Caski cell DNA was used as a 
positive control.13 During all amplifi cation procedure, a 
negative control including no targeted DNA was used. Am-
plifi cation procedure was performed by adding 5 µL ex-
tracted DNA to a mixture of 45 µL including 100 mM from 
each dNTP (dATP, dCTP, dGTP, dTTP) 100 pmol from 
each primer and 1 unit of Taq DNA polymerase enzyme 
(DNA mp ltd., Hants, UK) in 4 mM MgCl2, 50 mM KCl2, 
and 10 mM Tris HCl (pH 9.0). 
A thermal cycler programme with 35 cycles includ-
ing initial denaturation at 94°C for 5 min, denaturation 
at 94°C for 20 seconds, annealing at 55°C for 45 seconds 
and extension at 72°C for 1 min, followed by 7 min of fi nal 
extension at 72°C was performed. PCR products were ana-
lyzed on agarose gel stained with ethidium bromide and 
bands were detected with UV transluminator encompass-
ing 450 bp for HPV.11
Genotyping
MY09/MY14 (5’ - CAT ACA CCT CCA GCA CCT AA - 
3’) and MY09/WD74 (5’-GGA TGC TGC ACC GGC TG 
A-3’) specific primers were used for amplification of HPV 
type 16 and HPV type 18, respectively.12,14 
Amplification procedure was performed by adding 
5 µL pure DNA to a mixture of 95 µL including 
100 mM from each dNTP (dATP, CTP, dGTP, 
dTTP) 100 pmol from each primer and 1 unit of Taq 
polymerase in 4 mM MgCl2, 50 mM KCl2, and 10 mM 
Tris HCl (pH 9.0). We used a thermal cycler programme 
for HPV genotyping as described above. PCR products 
were analyzed on agarose gel stained with ethidium bro-
mide and transluminating band was detected with UV 
transluminator encompassing 110 bp for HPV 16 and 140 
bp for HPV 18.
Real-time PCR for CMV and HSV-2
Real-time PCR reactions were carried out by using Ligth-
cycler (Roche Diagnostics, Germany). Ligthcycler DNA 
master hybridization probes kit (Roche) was used for 
amplification. Taqman probes labeled with FAM at their 
5’ end and labeled with TAMRA as quencher at their 
3’ end, and specific primer sets for HSV DNA polymer-
ase gene region and CMV pp65 gene region (Table 1) 
were used for amplifications (Metis Biotechnology An-
kara, Turkey). 
Table 1. Primers and probes
Agent Region Primers (5 > 3)
HSV DNA polymerase CAT CAC CGA CCC GGA GAG 
GGA C
HSV DNA polymerase GGG CCA GGC GCT TGT TGG 
TGT A
CMV pp65 CTT GCC CTG GAT GCG ATA CT
CMV pp65 ACG GCT TTA CGG TGT TGT GT
Probes
HSV LC (TaqMan Probe) FAM- CCG CCG AAC TGA GCA 
GAC ACC CGC GC –TAMRA
CMV LC (TaqMan Probe) FAM- CGC GAG ACC GTG GAA 
CTG CG –TAMRA
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In each assay, fi ve CMV AD 169 DNA standards from 
2x102 to 2x106 CMV DNA copy/mL were used as external 
standards. A capillary tube containing distilled water instead 
of DNA was used as negative control in each run. The de-
tection limit was established as 200 CMV DNA copy/mL in 
blood. Serial dilutions containing 2x102-2x106 HSV DNA 
were prepared for HSV and a limit was detected as 200 HSV 
DNA copy/mL. A negative control was used in each study.
CMV serology
Anti-CMV IgM antibody: specifi c IgM responding to CMV 
in cervicovaginal smear samples was studied with two differ-
ent methods: microparticle enzyme immunoassay (MEIA) 
system and its appropriate anti-CMV IgM kit (Imx System, 
Abbott Laboratories, Abbott Park, IL, USA) and a commer-
cial diagnostic anti-CMV IgM enzyme-linked immunosorb-
ant assay (ELISA) kit (Radim SPA, Pomezia-Rome, Italy).
Anti-CMV IgG antibody: specifi c IgG responding to 
CMV in cervicovaginal smear samples was studied with 
MEIA system and its appropriate anti-CMV IgG kit (Axsym 
System, Abbott Laboratories, Abbott Park, IL, USA).
CMV IgG avidity test: the cervicovaginal smear sample 
with 4 U/mL of anti-CMV IgG were studied with a com-
mercial diagnostic CMV IgG avidity Enzyme immunoassay 
(EIA) kit (Radim SPA, Pomezia-Rome, Italy) according to 
the manufacturer’s instructions.
HSV serology
HSV-2 IgM and IgG antibodies were detected by EIA (Med-
dens Diagnostics B.V., The Netherlands) in the sera samples. 
Quantitative EIA was performed for HSV 2 IgG Ab accord-
ing to the manufacturer’s instructions. 
RESULTS
Patients and USG ﬁ ndings
All pregnants and the control group were monogamic and 
had no history of sexual intercourse before getting married. 
The reported age at fi rst sexual intercourse was less than 
20 years for 98 (73.1%) pregnants, and 67 (67.7%) of con-
trol group respectively. Of the 134 pregnants, 32 (23.8%) and 
99 controls 35 (35.4%) reported ever use of condoms for STDs. 
Of the 134 pregnants, 22 had abnormal ultrasonographic 
fi ndings, four oligohydramnios, four ventriculomegaly, three 
intrauterine growth retardation (IUGR), three IUGR + oligo-
hydramnios, two polyhydramnios, one bilateral choroid plexus 
cyst greater than 7 mm, one echogenic bowel + choroid plexus 
cyst, one polihydramnios, one omphalocele, one multiple struc-
tural abnormalities and one hydrops fetalis were detected.
Out of three pregnants with IUGR + oligohydramnios, one 
was found to be positive for CMV. All other pregnants with ab-
normal ultrasonographic fi ndings were found to be negative 
for each of the three viruses. No abnormal USG fi ndings were 
detected in any of the control group. 
Serology for CMV and HSV
Anti-CMV IgM was found to be negative in all of the cervicov-
aginal smear samples. In all of the samples studied, one cervi-
covaginal smear sample was found to be 4 U/mL, with negative 
result. Because both tests for anti-CMV IgM, and CMV IgG 
were designed for only serum evaluation, the cut-off values for 
smear may be lower than the cut-off values (10 U/mL) accepted 
for serum. In this respect the cervicovaginal smear sample with 
4 U/mL of anti-CMV IgG value was also approved as positive 
and studied with CMV IgG avidity test.
CMV IgG avidity test: according to the kit that we used, we 
considered the values below 35% as a low avidity, values be-
tween 35% and 45% as a gray zone and above 45% as a high 
avidity. Low avidity is a fi nding in favor of a primary acute in-
fection. The cervicovaginal smear sample with 4 U/mL of anti-
CMV IgG value was also studied with CMV IgG avidity test 
and again low avidity (21%) was found. This situation was also 
suggested a primary acute infection. 
HSV-2 Ig M and IgG were positive in the sera samples of 6 
(4.4 %) and 9 (9 %) of pregnants, respectively.
In house PCR and RT PCR for CMV, HPV and HSV-2
CMV DNA was found to be positive in two (1.5%) of pregnant 
women by real-time PCR. In control group there was no CMV 
DNA positivity. In one of the CMV positive pregnant women, 
there were abnormal USG fi ndings (oligohydroamnios and in 
utero growth retardation) (Table 2).
Table 2. One of two CMV positive pregnants had abnormal ultrasonographic finding. CMV DNA was negative 
for HPV type 18 positive 3 pregnants, while one of 3 was detected positive for HSV-2
                        CMV                            HSV-2 
  Positive Negative Positive Negative Total
HPV Type 18 
 Positive - 3 (2.1%) 1 (0.7%)** 2 (1.4%) 3 (2.1%)
 Negative 2 (1.4%) 132 (98.6%) 2(1.4%) 132(98.6%) 131(97.8%)
Abnormal USG  1*(5%) 20 (95%) - 21 (100%) 21(100%)
Total  2 (1.4%) 132 (98.6%) 3 (2.1%) 131(97.8%) 134 (100%)
*: abnormal USG findings
**:dual infections (HPV and HSV-2)
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Three (3/134; 2.2%) of pregnant women were found to 
be positive for only HPV 18. No other types of HPV were 
detected in any of the pregnants (Figure 1). In control group, 
there was no HPV DNA positivity.
Autopsy and CMV PCR from these materials could not be 
performed since the family did not give permission. The 
other CMV DNA positive pregnant woman gave a healthy 
birth and no problems occurred with the mother and baby 
during follow-up. 
Previous studies have shown that the incidence of CMV 
excretion from cervix increases while pregnancy proceeds.15 
In our study group, the patients were at their second trimes-
ter. In Turkey, Koksal et al.,16 Kaleli et al.17 and Satilmis et al.18 
reported the prevalence of CMV IgG in pregnant women 
as 79%, 94.7% and 98.5%, respectively. CMV IgM positivity 
in pregnancy was reported as 0.66% by Kaleli et al..17 It is 
determined that virus spread with asymptomatic infection 
is frequent among pregnant women and virus can be iso-
lated from cervical mucus and urine of 2%-28% of pregnant 
women.19 There are several potential routes of infection of 
the placenta during pregnancy, including ascending infec-
tion from the genital tract as well as hematogenous trans-
mission. As CMV secretion from cervix increases during 
pregnancy, a large spectrum of cells of the fetus is infected 
by CMV. The major target fetal organs for CMV infection 
are  the lungs, pancreas, kidneys and the liver but comparing 
with these organs, CMV DNA level determined in uterine 
tissue and cervical smear is higher.20
In our study, 134 pregnant women were screened for 
HSV-2 DNA. Three (2.2%) pregnant women and 2 (2%) 
women in control group were found to be positive in fa-
vour of HSV-2. In our country, HSV-2 is rarely seen due 
to the monogamy in the sexual relations. Genital herpes 
resulting from HSV-2 infection of the urogenital tract is 
a worldwide public health problem. European investiga-
tions of pregnant women have shown overall prevalence 
of HSV-2 to range between 9% and 33%.21 HSV-2 DNA 
prevalence was reported as 2% in Turkish pregnants re-
cently.22 Transmission of HSV is usually via direct contact 
with lesion while HSV-2 is classically transmitted sexually.6 
The women most at risk for mother to child transmission 
are the ones who are previously uninfected. New onset HSV 
infection in late pregnancy carries a 30%-50% risk of neo-
natal infection since there is not an adequate time for anti-
bodies to develop and suppress the viral replication before 
labor, while infection in early pregnancy carries a risk of less 
than 1%.6,23 Fortunately the risk of fetal infection in recur-
rent episodes is nearly 2%.24 Risk for baby usually happens 
during delivery via contact with genital lesions with recur-
rent episodes of viral shedding; therefore, caesarean section 
is recommended in these cases.25 In pregnant population, 
real-time PCR has some advantages, making results avail-
able at a much earlier time, thus signifi cantly reducing the 
need for empirical treatment.23,26 Dual infection with HPV 
and HSV positivity was found in one patient in our study. 
Any gynecological examination fi ndings were not found out 
in favor of HPV and HSV in any of the patients. Of the three 
CMV, HSV and HPV in Turkish pregnants
Figure 1: A; (HPV) M: fX174 DNA / Hae III marker. Lanes 1, 
2, 3: HPV positive patients. Lanes 4, 5: Negative control, B; 
(HPV type 18), M: fX174 DNA / Hae III marker. Lanes 1, 2, 3: 
HPV type 18 positive patients. Lane 4: Positive control. Lane 
5: Negative control.
Three (3/134; 2.2%) of the samples from the pregnant 
women were found to be positive for HSV-2. Dual infection 
with HPV and HSV positivity was found in one patient. Any 
gynecological examination fi ndings were not found out in 
favor of HPV and HSV in any of the patients (Table 2).
None of the pregnants and the control group had triple 
infection with CMV, HSV-2 and HPV. While there was no 
positivity for both CMV and HPV, HSV was found to be 
positive in 2 (2%) samples in control group.
DISCUSSION
In this study, of the 134 pregnant women, CMV DNA was 
found to be positive in two (1.5%) patients, while no CMV 
DNA positivity was found by real-time PCR in control 
group. In one of the CMV positive pregnant women, there 
were abnormal USG fi ndings (oligohydroamnios and in utero
growth retardation). She was followed for IUGR and 
in utero exitus happened during the 20th week of pregnancy. 
M  1 2 3 4 5 6
bp
140
AB
A
450
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HSV-2 DNA positive patients, all were HSV-2 IgM positive 
with no physical symptoms. These patients did not have a 
history of condom use before pregnancy and their fi rst sex-
ual intercourse were after the age of 20. Although they were 
asymptomatic, caesarean section was recommended for 
HSV positive three patients in our hospital and no problems 
occurred during the follow up of the mothers and babies.
Studies about HPV show that its transmission mode re-
mains unclear. HPV is positive in the airways of neonates 
and in maternal genital condylomas, which suggests that it 
is transmitted in the birth canal, from mothers with geni-
tal condylomas.27 Since the serologic diagnosis of HPV is 
inadequate, molecular diagnosis has been more popular 
in recent years.28 Epidemiological studies revealed differ-
ent results in pregnant women. Smith et al.,29 Gajewski et 
al.30 and Takakuwa et al.31 have found out 29%, 26% and 
12.5% of HPV positivity respectively in pregnant women 
taking routine obstetric care. In a study performed in our 
country, HPV DNA was found as 9.5% by PCR. One pa-
tient was found type 16/30, the others were untyped.32 We 
have found that 2.2% of the patients were positive for HPV 
18 in our study where Smith et al.29 found that 2.6% of the 
patients were positive in favor of HPV 18. The association 
between HSV-2 and HPV 18 was found in one of the preg-
nant women. This association may be due to the similar 
transmission route of both viruses. During the neonatal 
follow-up of baby HPV DNA was not found in the laryn-
geal swab by Real Time PCR.
CONCLUSION
Since HPV is considered as an infection predisposed to ma-
lignancies, HPV detection with molecular methods should be 
considered as a routine screening test for women applied to 
obstetrics and gynecology clinics. This screening policy should 
also contain CMV and HSV infections because of their poten-
tial transmission risks for the baby. We suggest that our assays 
provide useful information about CMV, HSV, HPV infections 
in the fetus and the neonate; and obstetricians have to make 
informed decisions about the management of pregnancies 
complicated by CMV, HSV, and HPV infections.
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